ASND:NSD-Ascendis Pharma A/S (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 95.40

Change

0.00 (0.00)%

Market Cap

USD 5.32B

Volume

0.40M

Avg Analyst Target

USD 167.41 (+75.48%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Ascendis Pharma A/S (ASND) Stock Analysis:
Based on the Ascendis Pharma A/S stock forecasts from 12 analysts, the average analyst target price for Ascendis Pharma A/S is USD 167.41 over the next 12 months. Ascendis Pharma A/S’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ascendis Pharma A/S is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Ascendis Pharma A/S’s stock price was USD 95.40. Ascendis Pharma A/S’s stock price has changed by +14.77% over the past week, -10.04% over the past month and -30.48% over the last year.

About

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCo ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

N/A

USD72.19B 9.35 7.18
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD65.33B 26.96 18.70
MRNA Moderna Inc

N/A

USD57.03B 4.22 2.75
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

N/A

USD38.17B 3.01 1.65
RPRX Royalty Pharma plc

N/A

USD26.82B 29.06 15.54
SGEN Seagen Inc

N/A

USD25.70B 55.02 44.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
GMAB Genmab A/S

N/A

USD19.45B 58.02 5.06
ARGX argenx SE

N/A

USD17.61B N/A N/A

ETFs Containing ASND

Symbol Name Weight Mer Price(Change) Market Cap
MEU:CA Mackenzie Maximum Diversi.. 0.00 % 0.56 %

N/A

USD0.01B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -29.09% 72% C- 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -29.09% 72% C- 41% F
Trailing 12 Months  
Capital Gain -30.48% 79% C+ 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.48% 79% C+ 43% F
Trailing 5 Years  
Capital Gain 266.22% 91% A- 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 266.22% 91% A- 92% A-
Average Annual (5 Year Horizon)  
Capital Gain 43.16% 78% C+ 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.16% 78% C+ 87% B+
Risk Return Profile  
Volatility (Standard Deviation) 52.20% 56% F 28% F
Risk Adjusted Return 82.69% 98% A+ 93% A
Market Capitalization 5.32B 96% A 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 93% A 98% A+
Price/Book Ratio 6.83 13% F 12% F
Price / Cash Flow Ratio -12.75 86% B 79% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -60.49% 48% F 20% F
Return on Invested Capital -52.42% 52% F 19% F
Return on Assets -24.29% 56% F 17% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 12.59 12% F 6% F
Short Percent 5.52% 43% F 31% F
Beta 0.85 75% C 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector